ArticleGland surgery2021
Tall cell carcinoma of the breast with reverse polarity: case report with gene sequencing and literature review.
Article in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Tall cell carcinoma with reversed polarity: case report of a rare special type of breast cancer and review of the literature.Discover oncology · 2025Article
- Tall cell carcinoma with reverse polarity of the breast in a young patient: A case report.International journal of surgery case reports · 2025Article
- Tall cell carcinoma with reversed polarity of breast cancer: a rare case report and review of the literature.Frontiers in oncology · 2025Article
- Clinicopathological characterization of tall cell carcinoma with reversed polarity of the breast: A case report and review of the litterature.International journal of surgery case reports · 2024Article
- Case report: Tall cell carcinoma with reversed polarity of the breast: an additional case and review of the literature.Frontiers in oncology · 2024Article
- Case report: Triple-negative breast cancer with low tumour-infiltrating lymphocytes infiltration and good prognosis: a case of Tall Cell Carcinoma with Reversed Polarity and review of the literature.Frontiers in oncology · 2024Article
- Tall Cell Carcinoma with Reversed Polarity: Case Report of a Rare Special Type of Breast Cancer and Review of the Literature.Biomedicines · 2023Article
- Codon 172 in theGland surgery · 2022Article
- Triple-negative breast carcinomas of low malignant potential: review on diagnostic criteria and differential diagnoses.Virchows Archiv : an international journal of pathology · 2022Review
- Review
- Tall cell carcinoma with reversed polarity: case report with gene sequencing and literature review.Gland surgery · 2021Article
Corrections and comments
- Commented on byCodon 172 in the2022
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tall cell carcinoma of the breast with reverse polarity (TCCRP), described firstly and also known as tall cell variant of papillary breast carcinoma (TCVPBC), is a rare type of breast cancer that mimics papillary thyroid carcinoma (PTC) histopathologically. As the incidence of this type of tumor is very low, awareness of it is crucial to ensuring that unnecessary clinical investigations are avoided. The present study examined a 45-year-old woman in China who was diagnosed with TCCRP. This paper outlines her demographic and clinicopathologic data, and her follow-up and immunohistochemical examination results. Furthermore, this study used the next-generation sequencing (NGS) technique to identify concurrent isocitrate dehydrogenase 2 (IDH2) and phosphatidylinositol 3-kinase catalytic alpha (PIK3CA) hotspot mutations. Notably, the novel results of the study showed that the IDH2 R120 (rather than the IDH2 R172) mutation may also be present in this disease. Additionally, a comprehensive literature review was conducted to elucidate some of the significant clinical and pathological features of this type of disease. This information may provide important insights that can be used in diagnosis and treatment. It is essential both for physicians and pathologists to recognize the existence of TCCRP, with its own specific clinical and pathological characteristics. Further research using molecular biology techniques should be conducted in the future to characterize this unique entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.